Post-earnings recap
Reported
Wed, Nov 2, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share that was slightly worse than expected, but the stock rose by 4.45% in response. Investors may be reacting positively to the company's ongoing clinical efforts despite the lack of revenue and guidance. The increase in stock price suggests that the market is optimistic about future developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | -5.47% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their ongoing projects but did not offer any updates on future expectations. The tone was cautious as they navigate the current market.
Management did not provide specific guidance for future performance.
The company is focused on advancing its clinical programs.